Fresh delay for $4.3B Roche/Spark deal triggers analyst concerns about gene therapy M&A
Roche CEO Severin Schwan may have prepared the staff at Spark for the fifth delay of its $4.3 billion acquisition — adding a few months …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
